HK inno.N Corporation
Clinical trials sponsored by HK inno.N Corporation, explained in plain language.
A pharmaceutical company developing and commercializing drugs and healthcare products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New injection aims to shed pounds in major obesity trial Results expected Dec 2026 (estimated)
- New GERD drug tegoprazan tested in large real-world study Results expected Jun 2027 (estimated)
- New diabetes shot aims to lower blood sugar in patients not helped by diet alone Results expected Aug 2027 (estimated)
-
New injection aims to restore strength in seniors with sarcopenia
Disease control Not yet recruitingThis Phase 2 trial tests an experimental drug called IN-207907 in 100 elderly people with sarcopenia, a condition causing muscle loss and weakness. Participants receive three doses of the drug or a placebo by IV every four weeks. The main goal is to see if the drug improves physi…
Phase 2 • Sponsor: HK inno.N Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New diabetes shot aims to lower blood sugar in patients not helped by diet alone
Disease control Not yet recruitingThis study tests an experimental injection called IN-B00009 in adults with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. About 110 participants will receive either the drug or a placebo to see if it safely lowers HbA1c levels over 24 weeks. …
Phase 3 • Sponsor: HK inno.N Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New injection aims to shed pounds in major obesity trial
Disease control Not yet recruitingThis study tests a new injection called IN-B00009 to help adults with obesity or overweight lose weight. About 300 people will receive either the drug or a placebo for 40 weeks. The main goals are to see how much weight they lose and if the treatment is safe.
Phase 3 • Sponsor: HK inno.N Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Could a week of acid drugs double as a GERD test?
Diagnosis Not yet recruitingResearchers are testing whether early symptom relief from tegoprazan can help diagnose gastroesophageal reflux disease (GERD). Adults with frequent heartburn or acid regurgitation take tegoprazan or a placebo once daily for one week. By comparing symptom improvement between the g…
Phase 4 • Sponsor: HK inno.N Corporation • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
New drug vs old drug: which one works better?
Knowledge-focused Not yet recruitingThis study compares two drugs, IN-M00007 and IN-R00007, to see if they are equivalent in healthy adults aged 19 to 59. Sixty volunteers will take a single dose of each drug in random order, and researchers will measure how the drugs are absorbed and how safe they are. The goal is…
Phase 1 • Sponsor: HK inno.N Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Healthy volunteers needed to test new Drug's effects
Knowledge-focused Not yet recruitingThis study looks at how a new tablet called IN-M00002 behaves in the body of healthy adults aged 19 to 55. It also checks how food and other medicines (tegoprazan and naproxen) affect the drug. The goal is to gather safety and drug-level information, not to treat any disease.
Phase 1 • Sponsor: HK inno.N Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC